AstraZeneca Results Presentation Deck
Continuing response to COVID-19
Advancing vaccine, antibody, other options
27
COVID-19 Vaccine
AstraZeneca
Late-stage trials recruited; >55k
participants
UK emergency use authorisation;
EU conditional marketing
authorisation
• US Phase III and additional data
from pooled Oxford trials during
Q1 2021
Granted conditional approval or
emergency use in >50 countries
AZD7442 long-acting
antibody (LAAB) combo
• PROVENT and STORMCHASER
Phase III trial in pre- and post-
exposure prophylaxis; 300mg IM¹
dose; potential for 12 months
protection
• TACKLE Phase III trial of 600mg IM
in outpatient setting and
collaborator trials
1. Intra-muscular.
First data
in H1 2021
Other COVID
efforts continue
Farxiga
DARE-19 Phase III trial
MEDI3506
ACCORD Phase II trial
Symbicort
INHASCO Phase Illa trial
• Pulmicort
TACTIC-COVID Phase Illa trial
STOIC Phase II trial positive
First data
in H1 2021
3View entire presentation